arrow
G

Gennaro Daniele

fondazione policlinico universitario agostino gemelli irccs
H指数:36
被引数:4,151

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Immune checkpoint inhibitors in platinum-resistant ovarian Cancer: Clinical disappointments, biological lessons, and the reopening of therapeutic opportunities

免疫检查点抑制剂在铂耐药卵巢癌中的应用:临床失望、生物学启示以及治疗机会的重新开启

2026-10-240
PRE
Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer

Sevabertinib治疗晚期HER2-Mutant非小细胞肺癌

2025-10-014
PRE
Performance status eligibility requirements and enrollment characteristics in cancer clinical trials leading to US Food and Drug Administration drugs approval (2009–2023)

癌症临床试验中与FDA药物审批相关的患者入组标准及基线特征(2009–2023)

2025-06-260
OA
An international survey on the knowledge, attitudes and clinical patterns of use of medical cannabis for cancer care: The TASMAN study
2025-01-010
PRE
Performance status restrictions in clinical trials leading to US food and drug administration (FDA) drug approval: A cross-sectional study of a decade (2014-2023)

临床 trials 中 performance status 限制与 US food and drug administration (FDA) 药物审批的关系:一项跨越十年(2014-2023)的横断面研究

2024-09-010
PRE
An open-label, first-in-human study of BAY2927088 in patients with advanced non-small cell lung cancer (NSCLC) harboring an EGFR and/or HER2 mutation
2023-04-141
PRE
Efficacy and safety of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: A systematic review and network meta-analysis

止吐方案治疗高度致吐性化疗引起的恶心和呕吐的有效性和安全性: 系统评价和网络荟萃分析

2023-04-0111
PRE
The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysis

作为评估细胞周期蛋白依赖性激酶4/6抑制剂在转移性乳腺癌中的临床影响和安全性的以患者为中心的工具,被帮助或伤害的可能性: 系统综述和敏感性分析

2023-02-015
OAAI
Integrating a Comprehensive Cancer Genome Profiling into Clinical Practice: A Blueprint in an Italian Referral Center

将全面的癌症基因组分析整合到临床实践中: 意大利转诊中心的蓝图

2022-10-209
OAAI